The Roxbury Institute Enhances Lipedema Care With Dr. Karen Herbst's Appointment

html

The Roxbury Institute, known globally for its contributions to lipedema treatment, has announced the appointment of Karen Herbst, Ph.D., M.D., as Head of Research and Director of Diagnostic and Preventative Medicine. This strategic partnership aligns with The Roxbury Institute's mission to advance the understanding and treatment of lipedema, a chronic disease characterized by abnormal fat distribution and swelling in the legs and arms, affecting millions of women worldwide.

This collaboration also aims to advance the treatment of other adipose connective tissue diseases, including lipolymphedema, Dercum’s disease, multiple symmetric lipomatosis, and lipodystrophy. Dr. Herbst, a board-certified endocrinologist, brings over two decades of expertise in researching lipedema and related diseases often misdiagnosed as obesity. She has made significant strides in characterizing the disease, earning her a global reputation as a leader in the field.

In her new role, Dr. Herbst will lead efforts to uncover the complexities of lipedema and associated diseases. Her research will focus on lymphatic and vascular comorbidities, metabolic and hormonal factors, and inflammatory implications. By integrating advanced research with innovative diagnostic and preventative therapies, she aims to set new standards of care for lipedema, complementing traditional surgical interventions.

"After more than a decade of acknowledging each other’s contributions to the field of lipedema, it’s an incredible honour to work closely with Dr. Herbst," said Dr. David Amron, The Roxbury Institute's founder and renowned specialist who has pioneered the surgical treatment of lipedema for over 25 years. "I’m certain that her research background and dedication to advancing treatment options beyond surgery will play an essential role in propelling our mission to vastly improve patient lives."

Dr. Herbst is highly esteemed within the medical community for her outstanding research contributions and initiatives. Her career includes notable achievements such as leading an NIH-sponsored conference in 2019 to establish the first Standard of Care Guidelines for Lipedema in the United States and introducing new ICD-10 codes for lipedema and Dercum's disease at the CDC.

"I am deeply honoured to collaborate with Dr. Amron in our shared mission to enhance the patient journey for those facing lipedema," said Dr. Herbst. "With our combined specialized knowledge in this often-overlooked field, we have an opportunity to uncover clinical breakthroughs focused on diagnostic and preventative solutions, and I anticipate we will develop life-changing treatments for patients worldwide."

Future Initiatives

Alongside her research initiatives, Dr. Herbst will maintain an active clinical practice, providing personalized care to both new and existing patients while collaborating closely with Dr. David Amron and his team of treatment specialists.

For more information or to learn more about scheduling an appointment with Dr. Herbst, visit www.advancedlipedematreatment.com/karen-herbst-phd-md.